COVID Clinical Trial
— COVICAREOfficial title:
An Observational Study of Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) to Determine the Degree of Myocardial Injury Using Biomarkers and Echocardiography, and the Impact of This on Cardiovascular Outcomes
NCT number | NCT04438993 |
Other study ID # | COVI-RW-2020 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 29, 2020 |
Est. completion date | January 29, 2021 |
Verified date | April 2022 |
Source | NHS Lanarkshire |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
An observational study of consecutive patients testing positive for COVID-19 who require admission to hospital to determine the degree of myocardial injury through biomarkers and echocardiography and the impact of this on cardiovascular outcomes. The COVID-19 disease and CARdiac Events study (COVICARE).
Status | Completed |
Enrollment | 100 |
Est. completion date | January 29, 2021 |
Est. primary completion date | January 29, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years 2. In-patient in UHH within first 5 days of admission 3. COVID-19 disease confirmed on rtPCR detection of SARS-CoV-2 from nasopharyngeal swabs and/or thoracic X-ray imaging findings characteristic of COVID-19 disease (positive swab results preferred). 4. Able to provide written, informed consent. Exclusion Criteria: 1. Refusal of consent for enrolment. 2. Known pre-existing left ventricular systolic dysfunction with left ventricular ejection fraction (LVEF) <40%. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospital Hairmyres | Glasgow | Scotland |
Lead Sponsor | Collaborator |
---|---|
NHS Lanarkshire |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiac abnormalities in COVID-19 disease in-patients | The primary objective of this study is to characterise the prevalence of myocardial injury and cardiac dysfunction in patients hospitalised with COVID-19 disease. | 6 months | |
Secondary | Biomarker - hsTnT | To compare levels of hsTnT in ng/L between patients who experience an adverse event and those who do not. | 30 days | |
Secondary | Biomarker - NT-proBNP | To compare levels of NT-proBNP in pg/ml between patients who experience an adverse event and those who do not. | 30 days | |
Secondary | Biomarker - ferritin | To compare levels of ferritin in ug/L between patients who experience an adverse event and those who do not. | 30 days | |
Secondary | Biomarker - cytokines | To compare levels of cytokines in pg/mL between patients who experience an adverse event and those who do not. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |